Abbott reports positive findings from Ph III Parkinson's disease study

US health care major Abbott Laboratories (NYSE: ABT) says that interim efficacy and safety results from a long-term, 54-week, Phase III open-label study of its investigational treatment for advanced Parkinson's disease showed that patients treated with levodopa-carbidopa intestinal gel (LCIG) for 12 weeks reported a decrease in "off" time and an increase in "on" time without troublesome dyskinesias. The results were reported at the International Congress of Parkinson's Disease and Movement Disorders in Toronto.

In an interim analysis of the long-term study, data were analyzed from 192 patients with advanced Parkinson's disease who had completed 12 weeks of treatment with LCIG for 16 hours per day. The primary efficacy endpoint is change from baseline to endpoint in "off" time at 54 weeks. At 12 weeks, patients reported an average of 3.9 fewer hours of "off" time and 4.6 additional hours of "on" time without troublesome dyskinesias.

AEs mostly related to surgical procedure